Oncotarget

Reviews:

Protease-activated receptor-1 (PAR-1): a promising molecular target for cancer

Xuan Liu, Jiahui Yu, Shangjin Song, Xiaoqiang Yue and Qi Li _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:107334-107345. https://doi.org/10.18632/oncotarget.21015

Metrics: PDF 3041 views  |   HTML 5314 views  |   ?  


Abstract

Xuan Liu1,2,*, Jiahui Yu2,*, Shangjin Song2, Xiaoqiang Yue2 and Qi Li1

1Department of Medical Oncology and Cancer Institute, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

2Department of Traditional Chinese Medicine, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China

*These authors contributed equally to this work

Correspondence to:

Qi Li, email: [email protected]

Xiaoqiang Yue, email: [email protected]

Keywords: PAR-1, cancer, carcinogenesis, invasion, metastasis

Received: June 24, 2017     Accepted: August 27, 2017     Published: September 18, 2017

ABSTRACT

PAR-1 is expressed not only in epithelium, neurons, astrocytes, immune cells, but also in cancer-associated fibroblasts, ECs (epithelial cells), myocytes of blood vessels, mast cells, and macrophages in tumor microenvironment, whereas PAR-1 stimulates macrophages to synthesize and secrete thrombin as well as other growth factors, resulting in enhanced cell proliferation, tumor growth and metastasis. Therefore, considerable effort has been devoted to the development of inhibitors targeting PAR-1. Here, we provide a comprehensive review of PAR-1’s role in cancer invasiveness and dissemination, as well as potential therapeutic strategies targeting PAR-1 signaling.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21015